ARMP
AMEXArmata Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$7.62-4.01 (-34.49%)
2026-03-042026-06-05
News · 26 weeks35-100%
2025-12-142026-06-07
Mix2890d
- Insider13(46%)
- SEC Filings9(32%)
- Other4(14%)
- Leadership2(7%)
Latest news
25 items- SECSEC Form 10-Q filed by Armata Pharmaceuticals Inc.10-Q - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- SECArmata Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- PRArmata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate UpdateEntered into secured credit agreement with Innoviva for $25 million maturing in 2029LOS ANGELES, May 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended March 31, 2026, and provided a corporate update. "Our top priority in 2026 is advancing Armata's lead Staphy
- SECArmata Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- PRArmata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential for Accelerated Approval and Priority Review upon successful clinical developmentAdvances AP-SA02 on a faster path to potential approval and patient access LOS ANGELES, May 7, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Fast Track Designation to AP-S
- PRArmata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"Describes structure of phage P7-1, included in Armata's Pseudomonas aeruginosa phage cocktail, AP-PA02 LOS ANGELES, May 4, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced a paper in Communications Biology, a peer-reviewed journal from Nature Portfolio. The publication, titled, "Structural atlas of Pakpunav
- INSIDERSEC Form 4 filed by Director Gilmer Daniel B.4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
- INSIDERSEC Form 3 filed by new insider Gilmer Daniel B.3 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
- SECSEC Form DEF 14A filed by Armata Pharmaceuticals Inc.DEF 14A - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- SECArmata Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- PRArmata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of DirectorsLOS ANGELES, April 27, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Daniel B. Gilmer, Ph.D. has joined the Company's Board of Directors, effective April 24, 2026. Dr. Gilmer has served as Senior Director, Commercial Quality U.S. Team Lead at Pfizer Inc. ("Pfizer") since February 2025. "I am pleased
- SECArmata Pharmaceuticals Inc. filed SEC Form 8-K: Other Events8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- SECSEC Form 10-K filed by Armata Pharmaceuticals Inc.10-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- SECArmata Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- PRArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial ResultsLOS ANGELES, March 25, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its fourth quarter and full-year ended December 31, 2025. Fourth Quarter 2025 Financial ResultsGrant Revenue. The Company recognized grant revenue of $1.1 million for the three months ended December 31, 2025 as com
- SECArmata Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- PRArmata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate UpdateLOS ANGELES, March 19, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it will delay the announcement of its financial results for its fourth quarter and full-year ended December 31, 2025, and provided a corporate update. The Company requires additional time to complete its financial reporting and ant
- INSIDERChief Business Officer Kyme Pierre covered exercise/tax liability with 1,030 shares, decreasing direct ownership by 10% to 9,461 units (SEC Form 4)4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
- INSIDERChief Executive Officer Birx Deborah covered exercise/tax liability with 4,919 shares, decreasing direct ownership by 2% to 212,458 units (SEC Form 4)4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
- INSIDERSEC Form 4 filed by Director Kramer Robin4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
- INSIDERSEC Form 4 filed by Chief Business Officer Kyme Pierre4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
- INSIDERSEC Form 4 filed by SVP, Finance, and PFO House David Duane4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
- INSIDERSEC Form 4 filed by Director Patti Joseph M4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
- INSIDERSEC Form 4 filed by Director Peterson Todd C.4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
- INSIDERSEC Form 4 filed by Director Odysseas Kostas D4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
ARMP FAQ
5 questionsWhat does Armata Pharmaceuticals Inc. do?
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for the treatment of Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing proprietary synthetic phage candidates to target...Where does ARMP stock trade?
Armata Pharmaceuticals Inc. (ARMP) is listed on AMEX.What sector and industry is ARMP in?
Armata Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What companies are similar to ARMP?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare ARMP side-by-side with any of them on Quantisnow.How can I track ARMP on Quantisnow?
Quantisnow aggregates Armata Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARMP to receive live email and push alerts on every new disclosure.